CATEGORIES:
A Original papers in peer-reviewed international scientific journals
B Review articles
C Published chapters in textbooks
D Abstracts published with citation in the scientific literature (Medline etc.)
E Papers in Norwegian Medical Journals
F Proceedings from International Symposia
G Monographs
H Publications in popular science magazines
I Varia

Download list of publications in Word format

A. Original papers in peer-reviewed scientific journals

Reisbig, R.R., and Bruland, Ø.S.: Dianthin 30 and 32 from Dianthus caryophyllus: Two inhibitors of plant protein synthesis and their tissue distribution. Arch. Biochemistry and Biophysics, 224, 700-706 (1983).

Reisbig, R.R., and Bruland, Ø.S.: The protein synthesis inhibitors from wheat, barley, and rye have identical antigenic determinants. Biochemical and Biophysical Research Communications, 114, 190-196 (1983).

Bruland, Ø.S., Fodstad, Ø., and Pihl, A.: The use of multicellular spheroids in establishing human sarcoma cell lines in vitro. Int. J. Cancer, 35, 793-798 (1985).

Bruland, Ø.S., Fodstad, Ø., Funderud, S., and Pihl, A.: New monoclonal antibodies specific for human sarcomas. Int. J. Cancer, 38, 27-31 (1986).

Fodstad. Ø., Brøgger, Ø., Bruland, Ø.S., Solheim, Ø.P., Nesland, J.M., and Pihl, A.: Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int. J. Cancer, 38, 33-40 (1986).

Godal, A., Bruland, Ø.S., Haug, E., Aas, M., and Fodstad, Ø.: Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells. Br. J. Cancer, 53, 839-841 (1986).

Bruland, Ø.S., Fodstad, Ø., Skretting, A., and Pihl, A.: Selective radiolocalization of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts. Br. J. Cancer, 56, 21-25 (1987).

Bruland, Ø.S., Fodstad, Ø., Stenwig, E. and Pihl, A.: Expression and characteristics of a novel human osteosarcoma-asociated cell surface antigen. Cancer Res., 48, 5302-5309 (1988).

Haines, D.M., and Bruland, Ø.S.: Immunohistochemical detection of (human) sarcoma-associated antigens in spontaneous canine osteosarcomas. Anticancer Res., 9, 903-908 (1989).

Fjeld, J.G., Bruland, Ø.S., Benestad, H.B., Schjerven, L., Stigbrand, T., and Nustad, K.: Radio-immunotargeting in immunocompetent animals using intraperitoneal diffusion chambers containing human tumor cells. Br. J. Cancer, 62, 573-578 (1990).

Flørenes, V.A., Aamdal, S., Myklebost, O., Mælandsmo, G.M., Bruland, Ø.S., and Fodstad, Ø.: Levels of nm23 messenger RNA in metastatic malignant melanomas: Inverse correlation to disease progression. Cancer Res., 52, 6088-6091 (1992).

Vergote, I.B., Larsen, R.H., DeVos, L.N., Nesland, J.M., Bruland, Ø.S., Bjørgum, J., Alstad, J., Trope, C.G., and Nustad, K.: Therapetic efficacy of the alpha-emitter 211At bound on microsheres compared with 90Y and32P colloids in a murine intraperitoneal tumor model. Gynecol. Oncol., 47, 366-372 (1992).

Haines, D.M., Bruland, Ø.S., Matte, G., Wilkinson, A.A., Meric, S.M., and Fowler, J.D.: Immunoscintigraphic detection of primary and metastatic canine osteosarcoma with F(ab')2 fragments of osteosarcoma-associated monoclonal antibody TP-1. Anticancer Res., 12, 2151-2158 (1992).

Kjønniksen, I., Winderen, M., Bruland, Ø.S., and Fodstad, Ø.: 99mTc MDP bone scans of human tumor xenografts in nude mice: Resemblance to corresponding lesions in the patient. Clin. Exp. Metastasis, 10, 54 (1992).

Andreasen, Å., Øyjord, T., Hovig, E., Holm ,R., Flørenes, V.A., Nesland, J. Myklebost, O., Høie, J., Bruland, Ø.S., Børresen, A.L., and Fodstad, Ø.: p53 abnormalities in different subtypes of human sarcomas. Cancer Res., 53, 468-471 (1993).

Kjønniksen, I., Winderen, M., Bruland, Ø.S., and Fodstad, Ø.: Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Res., 54, 1715-1719 (1994).

Lopes, J.M., Bjerkehagen, B., Holm, R., Bruland, Ø.S., Sobrinho-Simoes, M., and Nesland, J.M.: Immunohistochemical profile of synovial sarcomas with emphasis on the epithelial-type differentiation. A study of 49 primary tumors, recurrences and metastases. Path. Res. Pract., 190, 168-177 (1994).

Larsen, R.H., Bruland, Ø.S., Hoff, P., Alstad, J., Lindmo, T., and Rofstad, E.K.: Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: Comparison with 211At-labeled bovine serum albumin, free 211At, and external beam X-rays. Radiation Research, 139, 178-184 (1994).

Larsen, R.H., Bruland, Ø.S., Hoff, P., Alstad, J., and Rofstad, E.K.: Analysis of the therapeutic gain in the treatment of human osteosarcoma microclonies in vitro with 211At-labelled monoclonal antibodies. Br. J. Cancer, 69, 1000-1005 (1994).

Larsen, R.H., Hoff, P., Alstad, J., and Bruland, Ø.S.: Preparation and quality control of 211At-labelled and 125I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts. J. Labelled Compds. Radiopharm. 34, 773-785 (1994).

Hassfjell, S.P., Hoff, P., Bruland, Ø.S., and Alstad, J.: 212Pb/212Bi-EDTMP. Synthesis and biodistribution of a novel bone seeking alpha-emitting radiopharmaceutical. J. Labelled Compds. Radiopharm., 34, 717-734 (1994).

Page, R.L., Garg, P.K., Garg, S., Archer, G.E., Bruland, Ø.S., and Zalutsky, M.R.: Positron emission tomographic imaging of osteosarcoma in dogs using an 18F-labeled monoclonal antibody Fab fragment. J. Nucl. Med., 35, 1506-1513 (1994).

Bruland, Ø.S., Aas, M., Fodstad, Ø., Solheim, Ø.P., Høie, J., Skretting, A., Michaelsen, T., and Pihl, A.: Immunoscintigraphy of bone sarcomas. Results in five patients. Eur. J. Cancer, 30, 1484-1489 (1994).

Larsen, R.H., Hoff, P., Vergote, I.B., Bruland, Ø.S., Aas, M., De Vos, L., and Nustad, K.: Alpha-particle radiotherapy with 211At-labelled monodisperse polymer particles, 211At-labelled IgG proteins and free 211At in a murine intraperitoneal tumor model. Gynecol. Oncol., 57, 9-15 (1995).

Lopes, J.M., Bjerkehagen, B., Holm, R., Bruland, Ø.S., Sobrinho-Simoes, M., and Nesland, J.M.: The proliferative activity of synovial sarcomas. An immunohistohemical evaluation of Ki-67 labeling indices of 52 primary and recurrent tumors. Ultrastructural Pathology, 19, 101-106 (1995).

Olafsen, T., Bruland, Ø.S., Michaelsen, T., Zalutsky, M.R., and Sandlie, I.: Cloning and sequencing of the V-genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nucl. Med. Biol., 22, 765-771 (1995).

Larsen, R.H. and Bruland, Ø.S.: Radiolysis of radioimmunoconjugates. Reduction of antigen-binding ability by alpha-particle radiation. J. Labelled Compds. Radiopharm., 36, 1009-1018, 1995.

Gordeladze, J.O., Lund, H.W., Jablonski, G., and Bruland, Ø.S.: Diverse expression of G-proteins in human sarcoma cell lines with different osteogenic potential: Evidence for the involvement of Gi2 in cell proliferation. J. Cell. Biochemistry, 60, 95-106 (1996).

Bruland, Ø.S., Skretting, A., Solheim, Ø.P., and Aas, M.: Targeted radiotherapy of osteosarcoma using 153Sm-EDTMP. A new promising approach. Acta Oncol., 35, 381-384 (1996).

Hjelstuen, M.H., Rasch-Halvorsen, K., Brekken, C., Bruland, Ø.S., and de L. Davis, C.: Penetration and binding of monoclonal antibody in human osteosarcoma multicell spheroids. Comparison of confocal laser scanning microscopy and autoradiography. Acta Oncol., 35, 273-279 (1996).

Olafsen, T., Bruland, Ø.S., T., Zalutsky, M.R., and Sandlie, I.: Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3. Acta Oncol., 36, 297-301 (1996).

Moe, L., Boysen, M., Aas, M., Lønnaas, L., Gamlem, H., and Bruland, Ø.S.: Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. J. Small Animal Pract., 37, 241-246 (1996).

Sæter, G., Bruland, Ø.S., Follerås, G., Boysen, M., and Høie, J.: Extremity and non-extremity high grade osteosarcoma. The Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol., 35, s8, 129-134 (1996).

Lopes, J.M., Bruland, Ø.S., Bjerkehagen, B., Silva, C.M., Holm, R., Pettersen, E.O., Sobrinho-Simoes, M., Solheim, Ø.P., and Nesland, J.M.: Synovial sarcoma: Immunohistohemical expression of P-glycoprotein and glutathione transferase-pi and clinical drug resistance. Pathol. Res. Pract., 193, 21-36 (1997).

Hassfjell S., Bruland, Ø.S., and Hoff, P.: 212Bi-DOTMP - An alpha particle emitting bone seeking agent for targeted radiotherapy. Nucl. Med. Biol., 24 (3), 231-237 (1997)

Ekstrøm, P.O., Giercksky, K.E., Andersen, A., Bruland, Ø.S., and Slørdal, L.: Intratumoral differendes in methotrexate levels within human osteosarcoma xenografts as studied by microdialysis. Life Sciences, 61(19), 275-280 (1997).

Larsen, R.H., and Bruland, Ø.S.: Intratumor injection of immunoglobulins labelled with the alpha-emitter 211At: Analyses of tumor retention, microdistribution and growth delay. Br. J. Cancer, 77(7), 1115-1122 (1998).

Hassfjell, S., Skretting, A., Bruland, Ø.S., and Hoff, P.: Predicting detectability in radioguided surgery: A study based on physical characterization of the probe and on tissue uptake ratios of 125I-, 153Sm- and 165Er-labeled radiopharmaceuticals. Nucl. Med. Communic., 19, 207-217 (1998).

Larsen, R.H. and Bruland, Ø.S.: Preliminary evaluation of a new radiolabeled bisphosphonate. J. Labelled Compds. Radiopharm., 51, 823-830 (1998).

Olsen, D.R., and Bruland, Ø.S.: Radiotherapy in Scandinavia. Acta Oncol., 37(6), 553-560 (1998).

Lopes, J.M., Hannisdal, E., Bjerkehagen, B., Bruland, Ø.S., Danielsen, H.E., Pettersen, E.O., Sobrinho-Simoes, M., and Nesland, J.M.: Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. Anal. Cell. Pathol., 16, 45-62 (1998).

Olafsen, T., Rasmussen, I.B., Norderhaug, L., Bruland, Ø.S., and Sandlie, I.: IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eucaryotic cells. Immunotechnology, 4, 141-153 (1998).

Hjelstuen, M.H., Rasch-Halvorsen, K., Bruland, Ø.S., and de L. Davis, C.: Uptake, penetration and binding of monoclonal antibodies with increasing affinty in human osteosarcoma multicell spheroids. Anticancer Res., 18, 3153-3162 (1998).

Jemtland, R., Rian, E., Olstad, O.K., Haug, E., Bruland, Ø.S., Bucht, E., and Gautvik, K.M.: Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein. J. Bone and Mineral Res., 14, 904-914 (1999).

Larsen, R.H., Murud, K.M., Akabani, G., Hoff, P., Bruland, Ø.S., and Zalutsky, M.R.: 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J. Nucl. Med. 40, 1197-1203 (1999).

Aas, M., Moe, L., Gamlem, H., Skretting, A., and Bruland, Ø.S.: Internal radionuclide therapy in dogs with primary osteosarcoma employing 153Sm-EDTMP. Clin. Cancer Res., 5, 3148-3152 (1999).

Olafsen, T., Munthe Lund, C.K., Bruland, Ø.S., Sandlie, I., and Michaelsen, T.E.: Complement mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. Cancer Immunol. Immunther. 75, 755-783 (1999).

Ree, A.H., Tvermyr, M., Engebraaten, O., Rooman, M., Røsok, Ø., Hovig, E., Meza-Zepeda, L.A., Bruland, Ø.S., and Fodstad, Ø.: Expression of a novel factor of breast cancer cells with metastatic potential. Cancer Res., 59, 4675-4680 (1999).

Murud, K.M., Larsen, R.H., Bruland, Ø.S., and Hoff, P.: The influence of pre-treatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At- and 131I-labeled amidobisphosphonates in mice. Nucl. Med. Biol., 26/7, 791-794 (1999).

LeBourgeois, J.P. (on behalf of the Emesis Study Group in Radiotherapy Treatment, Bruland, Ø.S. member): Efficacy of an ondansetron orally disintegrating tablet: A novel formulation of this 5-HT3 receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and vomiting. Clinical Oncology, 11, 340-347 (1999).

Olsen, D.R., Bruland, Ø.S., and Davis, B.J.: Telemedicine in radiotherapy treatment planning - Requirements and Applications. Radiotherapy & Oncology, 54, 255-259 (2000).

Aurlien, A., Larsen, R.H., Olsen, D.R., and Bruland, Ø.S.: Alpha-particle radioimmunotherapy versus external beam irradiation of human osteosarcoma and bone marrow: Analyses of microdosimetry and cell survival. Int. J. Rad. Biol., 76/8, 1129-1141 (2000).

Brekken, C., Hjelstuen, M.H., Bruland, Ø.S., and de L. Davies, C.: Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res., 20/5, 3513-3519 (2000).

Ølberg, S, Skretting, A., Bruland, Ø.S., and Olsen D.R.: External irradiation of lung tissue: Dosimetric evaluation employing gel dosimetry. Phys. Med. and Biol., 45, 2761-2770 (2000).

Aurlien, E., Larsen, R.H., Kvalheim, G. and Bruland, Ø.S.: Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate 211-At-Rituximab against non-Hodgkin's lymphoma cells. Br.J.Cancer, 83, 1375-1379 (2000).

Brekken, C., Bruland, Ø.S., and de L. Davies, C.: Interstitial fluid pressure in human osteosarcoma xenografts: Significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res., 20/5, 353503-3512 (2000).

Hassfjell, S., Ingebrigtsen, K, and Bruland, Ø.S.: Synthesis, purification and biodistribution of 205Bi-DOTMP, visualizing bone deposition patterns with autoradiography. Nucl. Med. Biol., 28, 425-433 (2001).

Kvinnsland, Y., Skretting A., and Bruland, Ø.S.: Radionuclide therapy with bone-seeking radiopharmaceuticals: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone. Physics in Med. & Biol. 46, 1149-1161 (2001).

Onda, M., Olafsen, T., Tsutsumi, Y., Bruland, Ø.S., and Pastan, I.: Cytotoxicity of anti-osteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and truncated Pseudomonas Exotoxin A. J. of Immunotherapy, 24, 144-150 (2001).

Kvinnsland, Y., Bruland, Ø.S., Moe, L., and Skretting A.: A method for measurement of the utake patterns of two beta-emitting radionuclides in the same tissue ection with a digital silicon detector: Application to a study of 89-strontium and 153-samariumEDTMP in a dog with spontaneous osteosarcoma. Eur. J. Nucl. Med., 29, 191-197 (2002).

Anderson, P.M., Wiseman, G.A., Dispenzeri, A., Arndt, C., Hartman, L.C., Smithson, W.A., Mullan, B.P., and Bruland, Ø.S.: High dose 153-samarium Ethylene Diamine Tetramethylene Phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J.Clin.Oncology, 20/1, 189-196 (2002).

Aurlien, E., Kvinnsland, Y., Larsen, R.H., and Bruland, Ø.S.: Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation. Int. J. Radiat. Biol., 78/2, 133-142 (2002).

Ree, A.H., Bratland, A., Kroes, R.A., Aasheim, H.C., Flørenes, V.A., Moskal, J.R., Fodstad, Ø., Bruland, Ø.S., and Mælandsmo, G.M.: Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. Anticancer Res., 22, 1949-1958 (2002).

Chow, E, Jackson, S.Y., Hoskin, P., Cola, L.R., Bentzen, S.M., Blitzer, P.H (on behalf of the International Bone Metastases Consensus Working Party - Bruland, Ø.S. member): International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother. Oncology, 64, 275-80 (2002).

Henriksen, G., Breistøl, K, Bruland, Ø.S., Fodstad, Ø., and Larsen, R.: Significant antitumor effect from bone-seeking, alpha particle-emitting radium-223 demonstrated in an experimental skeletal metastases model. Cancer Res., 62, 3120-3125 (2002).

Dale, E., Hellebust, T.P., Bruland, Ø.S., and Olsen D.R.: Comparative analyses of the dynamic properties of the rectum studied by cryo-sections of human cadavers and pelvic CT-scans of patients. Br. J. Radiol., 76, 104-108 (2003).

Henriksen, G., Fisher, D.R., Roeske, J.C., Bruland, Ø.S., and Larsen, R.H.: Targeting of osseous sites with alpha emitting 223Ra: Comparison with beta emitter 89Sr in mice. J. Nucl. Med., 74/2, 252-259 (2003).

Olstad, O.K., Gautvik, V.T, Reppe, S., Jemtland, R., Rian, E., Ohlsson, C., Bruland, Ø.S., and Gautvik, K.: Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag-PCR subtration cloning. Anticancer Res., 23/3B, 2201-2216 (2003).

Henriksen, G., Bruland, Ø.S., and Larsen, R.: Thorium- and actinium polyphosphonate compounds as bone-seeking alpha particle emitting agents. Anticancer Res., 24, 101-106 (2004).

Davies, C.L.D., Lundstrøm, L.M., Frengen, J., Eikenes, L., Bruland, Ø.S., Kaalhus, O., and Brekken, C.: Radiation improves the distribution and uptake of liposomal doxorubicin (Calyx TM) in human osteosarcoma xenografts. Cancer Res., 64 547-553 (2004).

Henriksen, G., Schoultz, B.W., Michaelsen, T.E., Bruland, Ø.S., and Larsen, R.: Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl.Med.Biol, 31 441-449 (2004).

Mikkelsen, I.M., Løkke, C., Flægstad, T., and Bruland, Ø.S.: Interferon-gamma sensitises human osteosarcoma cells to TRAIL mediated apoptosis. Cancer Genomics & Proteomics, 1 95-104 (2004).

Eikenes, L., Bruland, Ø.S., Brekken, and Davies, C.deL.: Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res., 64 1555-60 (2004).

Bruheim, S., Bruland, Ø.S., Breistøl, K., Mælandsmo, G.M., and Fodstad, Ø.: Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol. Oncol. Research, 10/3 133-41 (2004).

Henriksen, G., Bruland, Ø.S., and Larsen, R.: Preparation and preclinical assessment of folate-conjugated radiolabeled antibodies. Anticancer Res., 25 231-36 (2005).

Onda, M., Bruland, Ø.S., and Pastan, I.: TP-3 immunotoxins improve antitumor activity in mouse bearing osteosarcoma. Clin. Orthop. Related Res. Clin. Orthopaedics and Rel. Res., 430 142-148 (2005).

Dale, E., Bruland, Ø.S., and Olsen D.R.: Comparative analyses of the dynamic properties of the bladder studied by repetitive pelvic CT-scans of patients and cryo-sections of cadavers. Br. J. Radiol., 78 528-32 (2005).

Nilsson, S., Balteskard, L., Fosså, S.D., Westlin, J.E.., Borch, K.W., Salberg, G., Larsen, R.H., and Bruland, Ø.S.: First clinical experiences with alpha emitter radium-223 in the treatment of skeletal metastases from breast and prostate cancer. Clin. Cancer Res. 11(12) 4451-59, (2005).

Bruland, Ø.S., Kleppe, H., Sæter, G., Smeland, S., and Fodstad, Ø.: Hematogenous micrometases in osteosarcoma patients. Clin. Cancer Res., 11(13) 4666-73, (2005).

Norum, J., Bruland, Ø.S., Spanne, O., Bergmo, T., Green, T., Olsen, D.R., Olsen, J.H., Sjåeng, E.E. and Brukow T.: Telemedicine in radiotherapy. A pilot study exploring remote treatment planning and supervision. Telemedicine, 11 245-50 (2005).

Brustugun, O.T., Reed, W., Poulsen, J.P and Bruland, Ø.S.: Primary osteosarcoma of the breast. Case reports and review of the literature. Acta Oncol., 44(7) 767-70 (2005).

Eikenes, L., Tari, M., Tufto, I., Bruland, Ø.S., and Davies, C.deL.: Hyaluronidase improves the distribution and uptake of liposomal doxorubicin (Calyx) in human osteosarcoma xenografts. Br. J. Cancer, 93 81-88 (2005).

Aksnes, L.H., Hall, K.S., Folleraas, G., Stenwig, A.E., Bjerkehagen, B., Taksdal, I., Winderen, Bruland Ø.S., and Saeter, G.: Management of high.grade bone sarcomas over two decades: The Norwegian Radium Hospital experience. Acta Oncol., 45 38-46 (2006).

Dahle, J., Borrebæk, J., Melhus, K.M., Bruland, Ø.S., Salberg, G., Olsen, D.R., and Larsen, R.H.: -radioimmunotherapy of lymphoma: Preclinical studies of? 227Th-DOTA-rituximab in Balb/c mice. Nucl. Med & Biol., 33 271-9 (2006).

Kaasa, S., Brenne, E., Lund, J-Aa, Fayers, P., Falkmer, U., Wallgren, A., Glas, U., and Bruland, Ø.S.: Prospective randomised multicenter trial on single fraction radiotherapy (8Gyx1) versus multiple fractions (3Gyx10) in the treatment of painful bone metastases. Radiotherapy & Oncology, 79, 278-84 (2006).

Larsen, R.H., Saxtorp, H., Skydsgaard, M., Borrebæk, J., Jonasdottir, T.J., Bruland, Ø.S., Klastrup, S. Harling, R., and Ramdahl, T.: Radiotoxicity of the alpha-emitting bone-seeker radium-223 injected intravenously in mice: Histology, clinical chemistry and haematology. In Vivo, 20(3), 325-31 (2006).

Jonasdottir, T.J., Fisher, D.R., Borrebæk, J., Bruland, Ø.S., and Larsen, R.H.: First in vivo evaluation of liposome-encapsulated Radium-223 as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res., 26, 2841-8 (2006).

Bruland, Ø.S., Nilsson, S., Fisher, D.R., and Larsen, R.H.: High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12(20), 6250s-6257s (2006).

Malinen, E., Søvik, Å., Hristov, D., Bruland, Ø.S., and Olsen, D.R. Adapting radiotherapy to hypoxic tumours. Phys. Medicine & Biology, 51, 4903-21 (2006).

Berg, A., Berner, A., Lilleby, W., Bruland, Ø.S., Fosså, S.D., Nesland, J.N., and Kvalheim, G.: Impact of disseminated tumor cells in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer, 120(8), 1603-9 (2007).

Søvik, Å., Malinen, E., Bruland, Ø.S., Bentzen, S.M., and Olsen, D.R.: Optimization of tumor control probability in hypoxic tumors by radiation dose redistribution. Phys Med Biol 52(2):499-513 (2007).

Aksnes, L.H., and Bruland Ø.S.: Some musculo-skeletal sequelae in cancer survivors. Acta Oncol 46(4), 490-6 (2007).

Porojnicu, A.C., Robsahm, T.E., Dahlback, A., Berg, J.P., Christiani, D., Bruland, Ø.S, and Moan, J.: Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? Lung Cancer 55(3), 263-70 (2007).

Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C, Valan MH, Bruland OS: Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm 22(3):431-7 (2007).

Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH: Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Blood 110(6):2049-56 (2007).

Søvik, Å., Malinen, E., Skogmo, H.K., Bentzen, S.M., Bruland, Ø.S., and Olsen, D.R. Radiotherapy adapted to spatial and temporal varialbility in tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys., 68(5), 1496-1504 (2007).

Nilsson, S., Franzén, L., Parker, C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D.C., Sokal, M., Pigott, K., Yachnin, J. Garkavij, M., Strang, P., Harmenberg, J., Bolstad, B., and Bruland, Ø.S.: Bone-targeted radium-223 in symptomatic, hormone refractory prostate cancer: A randomized, placebo-controlled, phase 2 study. Lancet Oncol. 8(7), 587-94 (2007).

Berg A, Lilleby W, Bruland OS, and Fosså SD: 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy. Int J Radiat Oncol Biol Phys 69(4):1074-83 (2007).

 

Erikson A, Tufto I, Bjønnum AB, Bruland, ØS, Davies Cde L: The impact of enzymatic degradation on the uptake of differently sized therapeutic molecules. Anticancer Res, 28 (6A), 3557-66(2008).

Dahle J, Bruland OS, and Larsen RH: Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Int J Radiat Oncol Biol Phys 72(1):186-92 (2008).

Berg A, Bruland OS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W: Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer. Prostate 68 (15), 1607-14 (2008).

Søvik A, Kippenes Skogmo H, Bruland ØS, Rune Olsen D, Malinen E: DCEMRI monitoring of canine tumors during fractionated radiotherapy. Acta Oncol 47(7):1249-56 (2008).

Porojnicu AC, Bruland OS, Aksnes L, Grant WB, Moan J: Sun beds and cod liver oil as vitamin D sources. J Photochem Photobiol B 91(2-3):125-31 (2008).

Vågane R, Bruland ØS, Fosså SD, Olsen DR: Radiological and functional assessment of radiation-induced pulmonary damage following breast irradiation. Acta Oncol 47(2):248-54 (2008).

Jebsen NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, Alvegård T, Bruland OS: Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study.
Int J Radiat Oncol Biol Phys 71(4):1196-203 (2008).

Berg A, Dahl AA, Bruland ØS, Bjøro T, Aanensen MS, Fosså SD: Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes. Prostate Cancer Prostatic Dis, 12 (3), 269-76 (2009).

Bruland ØS, Høifødt H, Hall KS, Smeland S, and Fodstad Ø: Bone Marrow Micrometastases Studied by an Immunomagnetic Isolation Procedure in Extremity Localized Non-metastatic Osteosarcoma Patients. In: Jaffe, Norman; Bruland, Øyvind S.; Bielack, Stefan (Eds.) Pediatric and Adolescent Osteosarcoma. Series: Cancer Treatment and Research , Vol. 152 , ISBN: 978-1-4419-0283-2, pp. 509-515, (2009).

Brandal P, Bjerkehagen B, Bruland OS, Skjeldal S, Bogsrud TV, Hall KS: Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience.
Acta Oncol, 48 (8), 1165-72 (2009).

Hall KS, Eriksson M, Bruland OS, Engellau J, Trovik CS: Treatment of soft tissue sarcoma of the extremity and trunk wall The Scandinavian Sarcoma Group perspective.
Acta Orthop., 80 S334, 52-59 (2009).

Norum OJ, Bruland ØS, Gorunova L, Berg K: Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model.
Int J Radiat Oncol Biol Phys, 75 (3), 878-85 (2009).

Revheim ME, Seierstad T, Berner JM, Bruland OS, Røe K, Ohnstad HO, Bjerkehagen B, Bach-Gansmo T: Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. Anticancer Res, 29 (11), 4331-6 (2009).

Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S: Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial. Radiother Oncol, 91 (2), 261-6 (2009).

Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA: Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol. Acta Orthop., 80 S334, 60-66 (2009).

Søvik S, Skogmo HK, Andersen EK, Bruland ØS, Olsen DR, Malinen E: DCEMRI of spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis.
Radiother Oncol, 93 (3), 618-24 (2009).

Vassiliou V, Bruland O, Janjan N, Lutz S, Kardamakis D, Hoskin P: Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness. Clin Oncol (R Coll Radiol), 21 (9), 665-7 (2009).

Bruland ØS, Bauer H, Alvegaard T, and Smeland S: Treatment of Osteosarcoma. The Scandinavian Sarcoma Group Experience. In: Jaffe, Norman; Bruland, Øyvind S.; Bielack, Stefan (Eds.) Pediatric and Adolescent Osteosarcoma. Series: Cancer Treatment and Research , Vol. 152 , ISBN: 978-1-4419-0283-2, pp. 309-318 (2009).

Schwarz R, Bruland OS, Cassoni A, Schomberg P, and Bielack S: The Role of Radiotherapy in Oseosarcoma. In: Jaffe, Norman; Bruland, Øyvind S.; Bielack, Stefan (Eds.) Pediatric and Adolescent Osteosarcoma. Series: Cancer Treatment and Research , Vol. 152 , ISBN: 978-1-4419-0283-2, pp. 147-164 (2009).

B. Review articles

Bruland, Ø.S.: Cancer therapy with radiolabeled antibodies. An overview. Acta Oncol., 34, 1085-1094 (1995).

Bruland, Ø.S., and Pihl, A.: On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur. J. Cancer, 33, 1725-1731 (1997).

Pihl, A., and Bruland, Ø.S. Oral presentation in science and medicine - An art in decline? Anticancer Res., 20, 2795-2800 (2000).

Reith, A., Olsen, D.R., Bruland, Ø.S., Bernder, A., and Risberg, B.: Information technology in action: The example of Norway. Stud. Health Technol. Inform. 96, 186-189 (2003).

Bruland, Ø.S., Nilsson, S., Fisher, D.R., and Larsen, R.H. High-linear energy-transfer irradiation targeted to skeletal metastases by the alpha emitter 223Ra: Adjuvant or alternative to conventional modalities? Clin Cancer Res., Clin Cancer Res 12(20), 6250s-6257s (2006).

Lipton, A., Berenson, J.R., Body, J.J., Boyce, B.F., Bruland, Ø.S., Carducci, M.A., Cleeland, C.S., Clohisy, D.R., Coleman, R.E., Cook, R.J., Guise, T.A., Pearse, R.N, Powles, T.J., Rogers, M.J., Roodman, G.D., Smith, M.R., Suva, L.J., Vessella, R.L., Weilbaecher, K.N., and King, L.: Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference.
Clin Cancer Res 12(20), 6209s-6212s (2006).

Olsen, D.R., Bruland, Ø.S., Frykholm, G., and Norderhaug I.N.: Proton therapy - A systematic review of clinical effectiveness. Radiother Oncol, 83, 123-32 (2007).


C Published chapters in textbooks

Bruland, Ø.S., Fodstad, Ø., Aass, M., and Pihl, A.: Monoclonal antibodies against human osteosarcoma. Preclinical studies. In: Srivastava, S.C.ed.: Radiolabeled monoclonal antibodies for imaging and therapy. ISBN 0 306 42982 9, Plenum Press, pp. 723-728 (1988).

Bruland, Ø.S., and Pihl, A.: Immunoscintigraphy and Radioimmunotherapy. Useful approaches in the management of osteogenic sarcoma? In: Novak,J.ed.: Frontiers of Osteosarcoma Research, Hogrefe & Huber, (ISBN 0-88937-113-x) 149-159 (1993).

Gordeladze, J.O., Jablonski, G., Paulssen, R.H., Paulssen, E.J., Mortensen, B.M., Weinstein, L., Gejman, P., and Bruland, Ø.S.: Modulation of hormonal signalling in human osteosarcoma cell lines. In: Novak,J.ed.: Frontiers of Osteosarcoma Research, Hogrefe & Huber, (ISBN 0-88937-113-x) 297-302 (1993).

Andreasen, Å., Børresen, A.L., Øyjord, T., Solheim, Ø.P., Flørenes, V.A., Bruland, Ø.S., Myklebost, O., Høie, J., and Fodstad, Ø.: Chromosome 17p aberrations and p53 expression in human sarcomas. In: Novak,J.ed.: Frontiers of Osteosarcoma Research, Hogrefe & Huber, (ISBN 0-88937-113-x) 419-422 (1993).

Skretting, A., Bruland, Ø.S., and Aas, M.: Absorbed dose estimation by combined use of CT information and whole body scanning with a dual head gamma camera in patients with osteosarcoma treated with 153Sm-EDTMP. In: Bergmann, Kroiss and Sinzinger (eds.): Radioactive isotopes in clinical medicine and research. Birkhauser Verlag, Basel, 383-386 (1997).

Larsen, R.H., Bruland, Ø.S., and Zalutsky: Radioimmunotherapy of osteosarcoma.: Future prospects. In Riva P. ed.: "Cancer therapy with monoclonal antibodies", Harwood Ac.Publ., ISBN90-5702-309-1, Amsterdam, 209-229 (1999).

Bruland Ø.S., and Pihl, A.: Targeted radiotherapy in the treatment of osteosarcoma. Radiobiological basis, clinical status and future prospects. In Abrams, P., and Fritzberg, A. eds. "Radioimmunotherapy of Cancer". Marcel Dekker Inc., ISBN0-8247-0277-8, New York, 323-337 (2000).

Bruland, Ø.S.: Sarkomer- Kreft i binde og støttevev. KREFTSYKEPLEIE - Pasient, Utfordring, Handling. (ISBN 82-7950-018-9) Reitan, A.M., and Schjølberg, T.K. (eds.) 447-452 (2000).

Bruland, Ø.S., Dahle, J., Olsen, D.R., and Larsen, R.H.: Targeted high-LET therapy of bone metastases. In: Tageted radionuclide tumor therapy - Biological aspects. Stigbrand, Adams & Carlsson (eds.). Springer Verlag. ISBN 978 1 4020 8695 3, pp. 181-194 (2008).

Bruland ØS, Hird A, and Chow E: Radiotherapy of Skeletal Metastases. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th Edition. The American Society for Bone & Mineral Research. ISBN 978 0 977 8882 1 4, pp. 404-406 (2008).

Jaffe, Norman; Bruland, Øyvind S. and Bielack, Stefan (eds.) Pediatric and Adolescent Osteosarcoma. Series: Cancer Treatment and Research , Vol. 152 , ISBN: 978-1-4419-0283-2, 2009.

Bruland ØS and Sartor O: Radioisotope treatments for bone metastases. In: Hanbook of Cancer-Induced Bone Disease. Comenan, Abrahamsson & Hadji (eds.) BioScientifica. In Press (2009).

D Abstracts published with citation in the scientific literature

Jablonski, G., Mortensen, B.M., Paulsen, R.H., Paulsen, E.J., Gautvik, K.M., and Bruland, Ø.S.: The effect of uremia and aluminum intoxication on hormone signalling in osteoblasts. J. Bone and Mineral Res., 7, 225 (1992).

Gordeladze, J.O., and Bruland, Ø.S.: The influence of the inhibitory G-protein G(I)2-alpha on growth-characteristics of human osteosarcoma cells. J. Bone and Mineral Res., 7, 224 (1992).

Ward, P., Misra, V., Bruland, Ø.S., Haines, D.H.: The molecular cloning of a gene encoding the TP-osteosarcoma-associated antigen. In: Reisfeld, R.A.ed.: Molecular approaches to cancer immunotherapy, Proc. Am. Assoc. Cancer Res., A-8 (1993).

Bartal, A.H., Wolf, J., Hirshaut, Y., Saric, O., Wolf, M., Bruland, Ø.S., and Pertschuk, L.P.: Monoclonal antibodies specific for osteosarcoma. Am. Soc. Cell Biol., Proceedings, 2148 (1993).

Bruland, Ø.S., Aas, M., Solheim, Ø.P., Winderen, M., and Høie, J.: Treatment of metastatic disease in osteosarcoma patients. New applications of radiolabelled poly- and bisphosphonates. Bone and Mineral, 25, 78 (1994)

Hjelstuen, M.H., Brekken, C., Bruland, Ø.S., and de L. Davis, C.: Penetration and binding of monoclonal antibodies in multicellular spheroids. Cytometry, 7, 90 (1994).

Bruland, Ø.S., Sæter, G., and Pihl, A.: Dilemmas and challenges in the current management of osteosarcoma. A plea for more individualized treatment. Anticancer Res., 15, 1798 (1995).

Moe, L., Aas, M., Skretting, A., and Bruland, Ø.S.: Comparative studies using 153Sm-EDTMP therapy in patients and dogs with spontaneous osteosarcoma. Anticancer Res., 15, 1794 (1995).

Bruland, Ø.S., Skretting, A., Sæter, G., Solheim, Ø.P., and Aas, M.: Targeted internal radiotherapy in osteosarcoma patients using 153Sm-EDTMP. Med. Ped. Oncol., 27, 215 (1996)

Monge, O., Følling, M., Hordvik, M., Hafslund, R., Lilleng, P., and Bruland, Ø.S.: Neo-adjuvant chemotherapy, conformal radiotherapy and intra-arterial 153samarium-EDTMP as primary treatment of high grade osteosarcoma of the spine. Acta Orthop Scand., 67, 48 (1996).

Sæter, G., Stenwig, A.E., Talle, K., Høie, J., Follerås, G., Solheim, Ø.P., Bruland, Ø.S., and Boysen, M.: Treatment of high-grade osteosarcoma localized outside the extremities - the Norwegian Radium Hospital / National Hospital experience. Acta Orthop Scand., 67, 50 (1996).

Bruland, Ø.S., Skretting, A., Winderen, M., Sæter, G., and Aas, M.: Targeted internal radiotherapy in patients with advanced osteosarcoma using 153Sm-EDTMP. Acta Orthop Scand., 67, 48 (1996).

Bruland, Ø.S., Høifodt, H., Sæter, G., and Fodstad, Ø.: Detection of microscopic disease in osteosarcoma - immunomagnetic isolation of tumor cells in peripheral blood and bone-marrow aspirates. Acta Ortop. Scand., S282, 34 (1998).

Aurlien, E., Larsen, R.H., Kvalheim, G. and Bruland, Ø.S.: Human lymphoma and bone marrow cells exposed to the alpha-emitting immunoconjugate astatine-211-Mabthera: Dose distributions and survival analyses. Cytotherapy 1/3, 239 (1999).

Olsen, D.R., Bruland, Ø.S., and Pettersen, E.O.: Can measurements of pre-treatment apoptotic fraction predict response to irradiation in hypoxic tumours? An analysis based on mathematical modelling. Int. J. Radiat. Oncol. Biol.Phys. 46(3), 717 (2000).

Olsen, D.R., Balteskard, L., Rinde, E., Sund, T., Bremnes, R., Bruland, Ø.S.: Telemedicine in radiotherapy. Radiother. Oncol. 56 (suppl. 1), 217, 2000.

Fodstad, Ø., Høifødt, H.K, Faye, R., Bruland, Ø.S., Holstad, L., Aamdal, S.: Immunomagnetic detection of micrometastatic cells in bone marrow predicts survival of patients with malignant melanoma and osteosarcoma. Proc. Am. Assoc. Cancer Res., #1542 (2001).

Bruland, Ø.S., Høifødt, H., Sæter, G., and Fodstad, Ø..: Micrometastases in patients with osteosarcoma. Anticancer Res., 21/3A, #202, 1627 (2001).

Saeter, G., Høie, J., Folleraas, G., Stenwig, A.E., Bjerkehagen, BV., Talle, K., Taksdal, I., Winderen, M., Helgerud, P., Sundby Hall, K., Bruland Ø.S., and Solheim, Ø.: Impact of multidisciplinary organization on treatment outcome: The Norwegian Radium Hospital Sarcoma Group experience. Int. J. Cancer, 13s, 52 (2002).

Brekken, C., Veliyulin, E., Singstad, T.E., Frengen, J., Eikenes, L., Davies, C.D., Bruland Ø.S., and Gribbestad, I.S.: Chemoirradiation of human osteosarcoma in mice: Early response assessment by magnetic reonance imaging. Int. J. Cancer, 13s, 95 (2002).

Kaasa, S., Brenne, E., Fayers, P., Lagerlung, M., Holmberg, M., Karlsberg, I., Falkmer, U., and Bruland, Ø.S.: Single fraction radiotherapy versus multiple fraction for treatment of painful bone metastases - A multicentre randomised trial. Int. J. Cancer, 13s, 136 (2002).

Haarsaker, V., Dale, E., Bruland, Ø.S., Hatlevoll, R., and Olsen, D.R.: Relationship between normal tissue complication probabilities and lung function in patients with lung cancer receiving radiotherapy. Int. J. Cancer, 13s, 457 (2002).

Eikenes, L., Bruland, Ø.S., and Davies C.D.L.: Collagenase increases the transcapillary gradient and the antibody uptake in human osteosarcoma xenografts. Int. J. Cancer, 13s, 151-52 (2002).

Larsen, R.H., Borch, K.W., Aas, M., Fossaa, S.D., Baltesgard, L., Traasdahl, E., Hess, S., Salberg, G., Henriksen, G., Schoultz, B.W., Nilsson, S., and Bruland, Ø.S.: Phase I clinical trial exploring the alphaemitting radium-223 against skeletal metastases: Blood clearance in patients with breast and prostate cancer. Int. J. Cancer, 13s, 285 (2002).

Gundersen, S., Holte, H., and Bruland, Ø.S.: Prognostic factors in patients with unknown primary neoplasms. Int. J. Cancer, 13s, 287 (2002).

Mikkelsen, I.M., Johnsen, J.I., Halvorsen, H., Bruland, Ø.S., and Flægstad, T.: Human osteosarcoma and neuroblastoma cell lines are sensitized to apoptosis by TRAIL and interferon-gamma treatment. Int. J. Cancer, 13s, 166 (2002).

Davies C.D.L., Bruland, Ø.S., and Tari, M.R.: Hylauronidase improves distribution of liposomal doxorubicin in human osteosarcoma xenografts. Int. J. Cancer, 13s, 425 (2002).

Smeland, S., Bruland, Ø.S., Jakobson, Aa, and Strander, H.: Is there a role for immunotherapy in the current management of osteosarcoma? Int. J. Cancer, 13s, 37-38 (2002).

Bruheim, S., Breistøl, K., Smith-Sørensen, B., Bruland, Ø.S., Mælandsmo, G.M., and Fodstad, Ø.: Sensitivity of human osteosarcoma to chemotherapy. Proc. Am. Assoc. Cancer Res., #107377 (2003).

Nilsson, S., Franzén, L., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Johannessen, D.C., Sokal, M., Petersson, U., Parker, C., Pigott, K., Yachnin, J. Garkavij, M., Harmenberg, J., Bolstad, B., Thuresson, M. and Bruland, Ø.S.: A randomized, placebo-controlled, phase 2 study of Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC) - Twelve month follow up data. ASCO-proceedings (2007).

Schwarz R, Carrle D, Kevric M, Bruland O, Bielack S, COSS. Results of radiotherapy in osteosarcoma. Strahlenther. Onkol., 185 Suppl 1, 6 (2009)

Nilsson S, Strang P, Franzèn L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C,  Bruland ØS,  Aksnes AK: A double-blind, randomised dose-response phase II, multicentre study of radium-223 (Alpharadin®) for the palliation of painful bone metastases in castration refractory prostate cancer patients. Eur J Cancer (2009).

Nilsson S, Franzèn L, Parker C, Bolstad B, Ramdahl T, Thuresson M and Bruland ØS: Alpha-emitting Radium-223: Two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer, Eur J Cancer (2009).

 

 

E. Papers in Norwegian Medical Journals

Sandven, P., and Bruland, Ø.S.: Forekomst av fotsopp hos rekrutter. TDNLF 23, 1526-1527 (1984).

Bruland, Ø.S.: "RADIO-IMMUNO-TARGETING", et nytt prinsipp i diagnose og behandling av kreft. Status og fremtidsmuligheter. Farmakoterapi, 56-69 (1991).

Bruland, Ø.S., and Nome, O.: Hyperkalsemi hos kreftpasienter. In: Cytostatika: Medikamentell kreftbehandling (5th edition). The Norwegian Cancer Society, 109-115 (1994).

Bruland Ø.S., Dahl, O., Monge, O., and Solheim, Ø.P.: Sarkomer - Informasjon om kreft i ben og bløtvev for pasienter, pårørende og andre interesserte. The Norwegian Cancer Society, 1-22 (1995).

Moe, L., and Bruland, Ø.S.: Veterinærer og humanmedisinere samarbeider om kreftbehandling: Redder dyr og mennesker. Anima, 2, 4-5 (1996).

Moe, L., and Bruland, Ø.S.: Osteosarkom hos hund. Ny form for strålebehandling under klinisk utprøving. Norsk Veterinærtidskrift 109-8/9, 518-520 (1997).

Tanum, G., Reitan, J.B., Bruland, Ø.S., and Hjelle, D.: Pasientbehandling ved strålingsulykker. Norwegian Radaiation Protection Authority - Strålevernhefte 14, ISSN 0804-4929 (1997).

Tanum, G., Bruland, Ø.S., Hjelle, D. and Reitan, J.B.: Pasientbehandling ved strålingsulykker. TDNLF (J. Norw. Med. Assoc.), 10, 1446-1450 (1999).

Bruland, Ø.S., Kvaløy, K., and Nome, O. Metabolske forstyrrelser ved kreft. Cytostatika 6.ed. The Norwegian Cancer Society & Inst. of Pharmacotherapy, 86-95 (1999).

Brendængen, M., Olsen, D.R. and Bruland, Ø.S.: Strålebehandling av skjelettmetastaser. TDNL, 16(120), 1870-1874 (2000).

Sæter, G., Sundby Hall, K., Bruland, Ø.S., Solheim Ø.P., Høie, J., Follerås, G., Helgerud, P., Stenwig, A.E., Bjerkehagen, B., Talle, K., Taksdal, I., and Winderen, M.: Bein- og bløtvevsarkomer behandlet ved Det Norske Radiumhospital: Utvikling over perioden 1980-1999. TDNLF - Journal of The Norwegian Medical Association, 122, 2089-94 (2002).

Brustugun, O.T., Nome. O., Bruland Ø.S., Ottestad, L. and Lilleby, W.: Brystkreftpasienters vurdering av ventetid før stålebehandling. TDNLF - Journal of The Norwegian Medical Association, 12/123, 1685-86 (2003).

Bruland, Ø.S. Å hoppe etter svenskene (Jumping after the Swedes). TDNLF - Journal of The Norwegian Medical Association, 126/5, 637 (2006).

Porojnicu, A.C., Berg, J.P., Dahlback, A., Juzeniene, A., Bruland, Ø.S, and Moan, J.: Solstråling, D-vitamin og kreft. TDNLF - Journal of The Norwegian Medical Association, Submitted.


F. Proceedings from International Symposia

Bruland, Ø.S. ed.: Comparative Osteosarcoma Research. First International Workshop. Proceedings, (1992).

Bruland, Ø.S. (ed.): Towards the eradication of osteosarcoma metastases: An Odyssey. 1-135 (Proceedings) ISBN 82-91929-02-5 (1998).

Bruland, Ø.S., and Pihl, A.: The many faces of osteosarcoma. Some dilemmas and challenges in its current management. 9-15 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Sæter, G., and Bruland, Ø.S.: High grade osteosarcoma: The scope beyond the classical patient. 21-23 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Høie, J., Sæter, G., Bruland, Ø.S., and Solheim, Ø.P.: Selection of patients for thoracotomy - Who can be cured by surgery? 62-64 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Bruland, Ø.S., Høifødt, H., Breistøl, K., Sæter, G., and Fodstad, Ø: Micrometastasis in patients with osteosarcoma. Immunomagnetic detection of tumor cells present in peripheral blood and bone marrow aspirates. 65-66 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Aurlien, E., Larsen, R.H., Olsen, D.R., and Bruland, Ø.S.: Selective eradication of micrometastases using astatine-211 labelled antibodies. 70-71 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Olafsen, T., Bruland, Ø.S., and Sandlie, I.: Construction and eucaryotic expression of chimeric anti-osteosarcoma TP-Mabs and fragments. 72 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Olsen, D.R., and Bruland, Ø.S.: Is osteosarcoma a radioresistant tumor? A radiobiological enigma. 73-76 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Moe, L., Aas, M., Gamlem, H., Skretting, A., Prestrud, K.W., and Bruland, Ø.S.: Spontaneous osteosarcoma in dogs: Clinical experience with targeted radionuclide therapy. 82-86 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Gautvik, K., Rian, E., Bruland, Ø.S., and Olstad, O.K.: Human osteosarcoma cells in bone research. 101-102 (Proceedings - "Osteosarcoma Odyssey") ISBN 82-91929-02-5 (1998).

Bruland, Ø.S., Harbitz, T., Wist, E., and Skjeldal, S. (eds.): Skeletal Metastasis - Current Therapies & Future Possibilities (2000).

Ramstad, G., and Bruland, Ø.S.: Helax-TMS User Meeting 2001 (Pamphlet containing CD-ROM). MDS Nordion Monographs, (2001).

Bruland, Ø.S., and Kvinnsland, S. (editors): UICC 18th International Cancer Congress - Spreading Knowledge to a Global Audience. Audiovisual & Inteactice CD-ROM. www.meddic.com/oslo ISBN 2-915254-05-2 (2003).

Bruland, Ø.S., and Flægstad, T.(editors): Targeted Cancer Therapies - An Odyssey. University Library of Tromsø, Ravnetrykk No. 29. ISBN 82-91378-32-0 (hard cover), 1-240 (2003)

Bruland, Ø.S.: External and internal radiotherapy in the treatment of skeletal metastases. "Skeletal complications of malignancy V. Philadelphia Oct 2007. Proceedings in: Clin. Exp.Metastasis. In Press (2007).

G. Monographs

Bruland, Ø.S.: Preparation and properties of two novel highly specific anti-sarcoma monoclonal antibodies and their application in the characterization and diagnosis of human sarcomas. Dissertation, (ISBN 82-90187-45-9) 1-60 (1988).

Bruland, Ø.S., Reitan, J.B., and Tanum, G.: Primærbehandling av pasienter ved strålingsulykker. Norwegian Radiation Protection Authority, ISBN 82-90362-09-9, 1-39 (1995).

Bruland, Ø.S., and Skjeldal, S. (eds.): Skeletal Metastasis - Diagnosis & Treatment. Novartis Oncology, 7, 1-101 (2000).

Bruland Ø.S., and Flægstad, T.(editors): Targeted Cancer Therapies - An Odyssey. University Library of Tromsø, Ravnetrykk No. 29. ISBN 82-91378-32-0 (hard cover), 1-240 (2003).

Kongsgaard, U., Kaasa, S., Dale, O., Ottesen, S., Nordøy, T., Hessling, S.E., von Hofacker, S., Bruland, Ø.S. and Lyngstadaas, A.: Lindring av smerter hos kreftpasienter. Medisinsk metodevurdering basert på internasjonale rapporter og egen litteraturgranskning. Nasjonalt kunnskapssenter for helsetjenesten. Rapport Nr. 9/2005, ISBN 82-8121-074-5, 254pages, (2005).

Olsen, D.R., Bruland, Ø.S., Frykholm, G. and Norderhaug, I.: Protonterapi. Medisinsk metodevurdering basert på internasjonale rapporter og egen litteraturgranskning. Nasjonalt kunnskapssenter for helsetjenesten. Rapport Nr. X/2006, 89 pages, (2006).


H. Publications in popular science magazines

Bruland, Ø.S.: Bisphosphonates. From the Laboratory to the Clinic. Leiras Inc. Monograph Series (1992).

Bruland, Ø.S. Skjelettmetastaser, hyperkalsemi og cancer. Organon Teknika. Interface Monograph Series (1993).

Pettersen, E.O., Olsen, D.R. and Bruland Ø.S.: Strålebiologisk forskning vil gi framskritt for strålebehandlingen. Kreftnytt 1, 9-12 (1997).

Bruland Ø.S., and Olsen, D.R.: Strålebehandling mot år 2000. Langs nye veier, eller "paa gjengrodde stier". Kreftnytt 1, 4-8 (1997).

Stuhaug, A., Bruland Ø.S., and Nilsson, S.: Nytt skyts mot benmetastaser. Legemidler & Samfunn, 23/7, 50-52 (2002).

Weinholdt, T. and Bruland, Ø.S.: Hei, jeg er vennen din! Dinamo Effect, Oslo, ISBN 82-8111-000-7, 1-35 (2003).

Bruland, Ø.S.: Noen onkologiske refleksjoner på Manhattan - Et reisebrev. Onkonytt, 1 5-9 (2004).


I .Varia

Bruland Ø.S.: Norwegian-American cooperation on tumor targeting drugs. Norwegian Cancer Society, "Annual Report", 12-13 (1997).

Pihl, A., and Bruland, Ø.S. Kreft, Helse & Politikk. Samtiden, 1, 56-68 (1999).

Bruland, Ø.S.: Hund på Radiumhospitalet. Bedre Helse, 7, 44-46 (2000).

Bruland, Ø.S.: "Tanker i Tresko - En kreftleges refleksjoner mellom Logos & Kaos". KREFTREGISTERET (Inst. of Population-based Cancer Research) Langmark, F., (ed.) 40-51 (2001).

Bruland, Ø.S.: "Terapihund - Til trøst og inspirasjon". In: Norges Blindeforbunds Skriftserie, 8-9 (2001).

Bruland, Ø.S.: Hund - Bra for helsa. KK (Kvinner & Klær), 50/11, 29-30 (2001).

Bruland Ø.S.: Hytter for enhver pris? In DNT-Årbok 2002 "Fjellenes år", The Norwegian Tourist Association, 77-81 (2002).

Pihl, A., and Bruland Ø.S.: On the spoken word in the scientific discourse. In: Targeted Cancer Therapies - An Odyssey. University Library of Tromsø, Ravnetrykk No. 29. ISBN 82-91378-32-0, 26-20 (2003).

Bruland Ø.S.: The concept of targeting. From mythology to modern medicine. In: Targeted Cancer Therapies - An Odyssey. University Library of Tromsø, Ravnetrykk No. 29. ISBN 82-91378-32-0, 18-23 (2003).

Larsen, R.H., and Bruland Ø.S.: Radium revisited. Targeting skeletal metastases by the alpha-emitter Radium-223. In: Targeted Cancer Therapies - An Odyssey. University Library of Tromsø, Ravnetrykk No. 29. ISBN 82-91378-32-0, 195-202 (2003).

Fauske, L, and Bruland Ø.S.: Falketind ad pionerruta. In DNT-Årbok 2004 "Bratt, Vått, Luftig", The Norwegian Tourist Association, ISBN 82 90339 61 5, 62-67 (2004).

Fauske, L, and Bruland Ø.S.: Falketind. I førstebestigernes fotspor. In "The Norwegian Alpine Club" - Tindeposten, 2, 8-13 (2005).

Olsen, D.R., and Bruland, Ø.S. Fusk og forskningskultur. Kronikk. Morgenbladet, June 2-8 p.18 (2006).

Bruland Ø.S.: Kreft - Årsaker og behandling. In: Livet med kreft. Red.: Knut Olav Åmås. Aschehoug. ISBN 978-82-03-23461-3 (2007).

Fauske, L., and Bruland Ø.S. (red.): Førstehjelp på tur - Fjell-, høyde- og reisemedisin. Fri Flyt - Norsk Tindeklub. ISBN 978-82-996 43252 (2007).

Åmås KO and Bruland ØS (eds.): Life with Cancer. Aschehoug, ISBN 978 82 03 23584 9 (2008).